Progress towards a hepatitis C virus vaccine
New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2013-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1038/emi.2013.79 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471031716085760 |
|---|---|
| author | Lok Man John Law Abdolamir Landi Wendy C Magee D Lorne Tyrrell Michael Houghton |
| author_facet | Lok Man John Law Abdolamir Landi Wendy C Magee D Lorne Tyrrell Michael Houghton |
| author_sort | Lok Man John Law |
| collection | DOAJ |
| description | New drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost, it is unlikely that these HCV drugs will substantially reduce the world’s HCV carrier population of around 170 million in the near future or the estimated global incidence of millions of new HCV infections. For these reasons, there is an urgent need to develop a prophylactic HCV vaccine and also to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. After much early pessimism on the prospects for an effective prophylactic HCV vaccine, our recent knowledge of immune correlates of protection combined with the demonstrated immunogenicity and protective animal efficacies of various HCV vaccine candidates now allows for realistic optimism. This review summarizes the current rationale and status of clinical and experimental HCV vaccine candidates based on the elicitation of cross-neutralizing antibodies and broad cellular immune responses to this highly diverse virus. |
| format | Article |
| id | doaj-art-25ee4ccf383f4de0b22c67c57efe0441 |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-25ee4ccf383f4de0b22c67c57efe04412025-08-20T03:24:57ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512013-01-01211710.1038/emi.2013.79Progress towards a hepatitis C virus vaccineLok Man John Law0Abdolamir Landi1Wendy C Magee2D Lorne Tyrrell3Michael Houghton4Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton T6G 2E1, CanadaLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton T6G 2E1, CanadaLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton T6G 2E1, CanadaLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton T6G 2E1, CanadaLi Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton T6G 2E1, CanadaNew drugs to treat hepatitis C are expected to be approved over the next few years which promise to cure nearly all patients. However, due to issues of expected drug resistance, suboptimal activity against diverse hepatitis C virus (HCV) genotypes and especially because of their extremely high cost, it is unlikely that these HCV drugs will substantially reduce the world’s HCV carrier population of around 170 million in the near future or the estimated global incidence of millions of new HCV infections. For these reasons, there is an urgent need to develop a prophylactic HCV vaccine and also to determine if therapeutic vaccines can aid in the treatment of chronically infected patients. After much early pessimism on the prospects for an effective prophylactic HCV vaccine, our recent knowledge of immune correlates of protection combined with the demonstrated immunogenicity and protective animal efficacies of various HCV vaccine candidates now allows for realistic optimism. This review summarizes the current rationale and status of clinical and experimental HCV vaccine candidates based on the elicitation of cross-neutralizing antibodies and broad cellular immune responses to this highly diverse virus.https://www.tandfonline.com/doi/10.1038/emi.2013.79HCVhepatitisinfectionprophylactictherapeuticvaccine |
| spellingShingle | Lok Man John Law Abdolamir Landi Wendy C Magee D Lorne Tyrrell Michael Houghton Progress towards a hepatitis C virus vaccine Emerging Microbes and Infections HCV hepatitis infection prophylactic therapeutic vaccine |
| title | Progress towards a hepatitis C virus vaccine |
| title_full | Progress towards a hepatitis C virus vaccine |
| title_fullStr | Progress towards a hepatitis C virus vaccine |
| title_full_unstemmed | Progress towards a hepatitis C virus vaccine |
| title_short | Progress towards a hepatitis C virus vaccine |
| title_sort | progress towards a hepatitis c virus vaccine |
| topic | HCV hepatitis infection prophylactic therapeutic vaccine |
| url | https://www.tandfonline.com/doi/10.1038/emi.2013.79 |
| work_keys_str_mv | AT lokmanjohnlaw progresstowardsahepatitiscvirusvaccine AT abdolamirlandi progresstowardsahepatitiscvirusvaccine AT wendycmagee progresstowardsahepatitiscvirusvaccine AT dlornetyrrell progresstowardsahepatitiscvirusvaccine AT michaelhoughton progresstowardsahepatitiscvirusvaccine |